![]() The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The 4 Wall Street analysts offering Co-Diagnostics stock forecast in the. Stock Forecast, Predictions & Price Target>Co Diagnostics Inc Stock. The average Co Diagnostics stock price prediction forecasts a potential upside. ![]() Start investing in Co-Diagnostics Inc stocks from India now with fractional. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2023 results on Thursday, May 11, 2023, after the market close. Buy Co-Diagnostics Inc Shares from India at 1.35 (0 Commission) today. The Co-Dx PCR Home is subject to FDA review and is not available for sale.Ĭo-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. Soleno Therapeutics Inc Stock Price Forecast, SLNO Predictons for2025. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for. SALT LAKE CITY, /PRNewswire/ - Co-Diagnostics, Inc. Attendees interested in learning more about the Company, including its upcoming Co-Dx PCR Home™ platform, are invited to visit Booth B4-04. The congress also features a hybrid format, to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities.Ĭo-Dx believes that the congress will provide opportunities for Company representatives and distributors to interface with a wide cross-section of potential international customers for the Company's real-time PCR products. ECCMID is described as one of the most comprehensive and influential congresses in infectious diseases, bringing together international experts in related fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues.
0 Comments
Leave a Reply. |